On July 23, 2019, the United States District Court for the District of Columbia released this ruling on the motion for summary judgement in the case Braeburn v. FDA & Indivior. The ruling states that Braeburn’s motion is granted; and both Indivior’s motion, and the FDA’s motion, are denied. This decision challenges the FDA’s determination that Brixadi Monthly cannot be finally approved until Sublocade’s three-year exclusivity expires . . .